AFT Stock Overview
Engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AFT passed our risk checks.
My Notes
Capture your thoughts, links and company narrative
AFT Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$2.80 |
| 52 Week High | NZ$3.85 |
| 52 Week Low | NZ$2.37 |
| Beta | 0.36 |
| 1 Month Change | 5.66% |
| 3 Month Change | -11.67% |
| 1 Year Change | -16.42% |
| 3 Year Change | -36.07% |
| 5 Year Change | -19.77% |
| Change since IPO | -9.68% |
Recent News & Updates
Recent updates
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 17
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year
Jul 26AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
May 25Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?
May 22Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?
Oct 17Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?
May 23Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?
Dec 01We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Jul 30With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
Jun 02Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?
Mar 20A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation
Feb 13
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 23Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?
Jan 02Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?
Dec 12AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 21Shareholder Returns
| AFT | NZ Pharmaceuticals | NZ Market | |
|---|---|---|---|
| 7D | -1.8% | -4.7% | 1.1% |
| 1Y | -16.4% | -10.0% | 6.1% |
Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: AFT underperformed the NZ Market which returned 6.1% over the past year.
Price Volatility
| AFT volatility | |
|---|---|
| AFT Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in NZ Market | 9.1% |
| 10% least volatile stocks in NZ Market | 3.1% |
Stable Share Price: AFT has not had significant price volatility in the past 3 months compared to the NZ market.
Volatility Over Time: AFT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 110 | Hartley Atkinson | www.aftpharm.com |
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals Limited Fundamentals Summary
| AFT fundamental statistics | |
|---|---|
| Market cap | NZ$293.63m |
| Earnings (TTM) | NZ$11.61m |
| Revenue (TTM) | NZ$198.51m |
25.3x
P/E Ratio1.5x
P/S RatioIs AFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFT income statement (TTM) | |
|---|---|
| Revenue | NZ$198.51m |
| Cost of Revenue | NZ$109.98m |
| Gross Profit | NZ$88.54m |
| Other Expenses | NZ$76.93m |
| Earnings | NZ$11.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 44.60% |
| Net Profit Margin | 5.85% |
| Debt/Equity Ratio | 36.0% |
How did AFT perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield16%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 10:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AFT Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Jack Crowley | Credit Suisse |
| Soo Romanoff | Edison Investment Research |